Short Sellers Circle Valneva as H1 Results Could Define the Stock’s Next Act
Published on 07/23/2026 at 18:33 | Redaktion boerse-global.de
The French-Austrian vaccine developer Valneva finds itself in an increasingly precarious position as its shares test fresh lows just weeks before a pivotal earnings release. On Thursday, the stock touched €2.08, a new 52-week trough, before edging back to €2.12. That leaves the equity nursing a year-to-date decline of nearly 43%, with the gap to its 52-week high of €5.16 from August 2025 now stretching to roughly 59%.
The selling pressure has attracted the attention of at least one prominent hedge fund. D.E. Shaw disclosed a net short position of 0.69% against Valneva on July 17, a move that looks prescient given the subsequent slide. The stock closed Wednesday at €2.14, down 0.93% on the session and just 1.67% above its yearly low. Over the past month alone, the shares have shed 8.21%.
Technicals Flash Oversold, But No Bounce Yet
The charts paint a grim picture. Valneva’s stock is trading 9% below its 50-day moving average of €2.34 and a staggering 37% under its 200-day average of €3.38. The 14-day relative strength index sits at 34.2, a level that typically signals oversold conditions, yet no reversal pattern has materialized. The annualized 30-day volatility of 22.19% underscores the persistent uncertainty surrounding the name.
H1 Report Arrives at a Tense Moment
All eyes are now trained on August 13, when Valneva will publish its first-half 2026 results, followed by a webcast at 3 p.m. CET. The report comes on the heels of a disappointing first quarter that saw product revenues tumble 37.2% year-over-year, blamed on one-off factors and softer demand for travel vaccines amid geopolitical tensions.
Should investors sell immediately? Or is it worth buying Valneva?
That miss forced management to trim its full-year revenue guidance by 7%, to a range of €135 million to €150 million. The company ended March with €105.3 million in cash — a figure that excludes proceeds from a successful April private placement — and has since launched a fresh cost-reduction program to shore up its finances. First Berlin Equity Research maintained its “Buy” rating but lowered its price target from €4.80 to €4.50, while the consensus analyst view tracked by TipRanks still calls for a “Buy” with a target of €5.60 — a level that implies significant upside but also highlights the chasm between Wall Street’s optimism and the market’s current pessimism.
The Lyme Vaccine: A Binary Catalyst
While the quarterly numbers will matter, the real focus for investors is the pipeline update, particularly around Valneva’s most advanced asset: the Lyme disease vaccine candidate LB6V, developed in partnership with Pfizer. Market observers assign a 67% probability of FDA approval, and the second half of 2026 is packed with milestones, including a pre-BLA meeting with Pfizer and the actual BLA submission to U.S. regulators.
Pfizer reported positive Phase 3 topline data earlier this year, showing strong efficacy and no safety concerns, setting the stage for regulatory filings. Any concrete update on the submission timeline during the August 13 webcast could move the stock independently of the financial results. Alongside the Lyme program, Valneva is also advancing what it calls the world’s most advanced shigellosis vaccine candidate, adding another potential catalyst to the mix.
Valneva at a turning point? This analysis reveals what investors need to know now.
What Comes Next
With the stock hovering just above its 52-week low and trading well below every major moving average, the next three weeks are likely to be dominated by positioning ahead of the H1 report. The short interest from D.E. Shaw adds another layer of tension, though the oversold RSI leaves technical room for a relief rally. Whether that materializes will depend less on the half-year revenue figures and more on whether Valneva can deliver a concrete update on the regulatory path for its Pfizer-partnered Lyme vaccine — and convince the market that its pipeline promise outweighs the commercial headwinds.
Ad
Valneva Stock: New Analysis - 23 July
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
